Kinase Inhibitors: Global Markets

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Definitions

• Enzymes
• Coenzymes

Enzyme Inhibitors

• Active Site
• Enzyme Inhibitors
• Why Enzyme Inhibition?
• Use of Enzyme Inhibitors
• Mechanism of Enzyme Inhibition
• Types of Enzyme Inhibitors
• Classification of Enzyme Inhibitors

Kinase Inhibitors

• History of Protein Kinases
• Type of Kinase Inhibitors
• Classification by Types of Amino Acid Phosphorylation
• Classification by Site of Action

Market Dynamics

• Drivers
• Market Restraints
• Opportunity

Chapter 4 Covid Impact on Market

Overview

• Short-Term Impact on Pharmaceutical Industry
• Long-Term Impact
• Current Outlook

COVID-19 Impact on Cancer Care

Chapter 5 Regulatory Scenario

Overview
Market Leaders and Their Products for Kinase Inhibitors

Chapter 6 Market Breakdown by Type

Introduction
Tyrosine Kinase Inhibitors

• Market Size and Forecast
• Market Analysis

Serine/Threonine Kinase Inhibitors

• mTOR Kinase Inhibitors
• B-Raf
• RHO Kinase Inhibitors
• Cyclin-Dependent Kinase Inhibitors
• Aurora Kinase Inhibitors
• MAP/MEK Kinase Inhibitors
• JNK Inhibitors
• Protein Kinase C Inhibitors
• PI3K Inhibitors
• Market Size and Forecast
• Market Analysis

Chapter 7 Market Breakdown by Application

Introduction
Antineoplastic Agents

• Market Size and Forecast
• Market Analysis

Age-related Macular Degeneration (AMD)

• Market Size and Forecast
• Market Analysis

Immunosuppressant

• Market Size and Forecast
• Market Analysis

Chapter 8 Market Breakdown by Region

Introduction
North America

• Market Analysis
• U.S.
• Canada

Europe

• Market Analysis
• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific

• Market Analysis
• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Market Size and Forecast
• Market Analysis

Chapter 9 Industry Developments

Company Share Analysis
Pipeline Analysis
Patent Analysis
Current Scenario
Cancer and Kinase Inhibitors
Multiple Single Kinase Inhibitors Vs. Single Multikinase Inhibitors

• Efficacy
• Resistance
• Pharmacokinetics
• Selectivity
• Tumor Microenvironment
• Toxicity

Future Directions

Chapter 10 Company Profiles

Leading Companies
ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON
NOVARTIS AG
PFIZER
Other Manufacturers
ASTELLAS PHARMA INC.
AVEO PHARMACEUTICALS, INC.
EXELIXIS INC.
MERCK KGAA
SANOFI
TAKEDA PHARMACEUTICAL CO., LTD.
Chapter 11 Appendix A: Abbreviations and Acronyms

List of Tables

Summary Table A : Global Market for Kinase Inhibitors, by Type, Through 2026
Summary Table B : Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2026
Table 1 : Classification of Enzyme Inhibitors
Table 2 : History of Protein Kinases
Table 3 : ATP-Competitive and Non-Competitive Inhibitors
Table 4 : Types of Serine/Threonine Kinase Inhibitors
Table 5 : Types of Receptor Tyrosine Kinase Inhibitors
Table 6 : Types of Non-Receptor Tyrosine Kinase Inhibitors
Table 7 : Classification of Kinase Inhibitors by Site of Action
Table 8 : Patent Expiration Dates of Kinase Inhibitors
Table 9 : Coronavirus Reported Cases and Deaths, by Country, May 2021
Table 10 : FDA-Approved Kinase Inhibitors, 2001-2021
Table 11 : FDA-approved Kinase Inhibitors and Their Drug Targets
Table 12 : EMA-approved Kinase Inhibitors, 2001-2020
Table 13 : Safety Alerts and Warnings for Kinase Inhibitors
Table 14 : Leading Manufacturers and Suppliers of Receptor Tyrosine Kinase Inhibitors
Table 15 : Leading Manufacturers and Suppliers of Non-Receptor Tyrosine Kinase Inhibitors
Table 16 : Leading Manufacturers and Suppliers of Serine/Threonine Tyrosine Kinase Inhibitors
Table 17 : Global Market for Kinase Inhibitors, by Type, Through 2026
Table 18 : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2026
Table 19 : Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2026
Table 20 : Global Market for Serine/Threonine Kinase Inhibitors, by Region, Through 2026
Table 21 : Global Market for Kinase Inhibitors, by Application, Through 2026
Table 22 : Global Market for Kinase Inhibitors Used as Antineoplastic Agents, by Region, Through 2026
Table 23 : Global Market for Kinase Inhibitors Used in Age-related Macular Degeneration, by Region, Through 2026
Table 24 : Global Market for Kinase Inhibitors Used as Immunosuppressants, by Region, Through 2026
Table 25 : Global Market for Kinase Inhibitors, by Region, Through 2026
Table 26 : North American Market for Kinase Inhibitors, by Type, Through 2026
Table 27 : North American Market for Tyrosine Kinase Inhibitor, by Type, Through 2026
Table 28 : North American Market for Kinase Inhibitors, by Application, Through 2026
Table 29 : North American Market for Kinase Inhibitors, by Country, Through 2026
Table 30 : European Market for Kinase Inhibitors, by Type, Through 2026
Table 31 : European Market for Tyrosine Kinase Inhibitor, by Type, Through 2026
Table 32 : European Market for Kinase Inhibitors, by Application, Through 2026
Table 33 : European Market for Kinase Inhibitors, by Country, Through 2026
Table 34 : Asia-Pacific Market for Kinase Inhibitors, by Type, Through 2026
Table 35 : Asia-Pacific Market for Tyrosine Kinase Inhibitor, by Type, Through 2026
Table 36 : Asia-Pacific Market for Kinase Inhibitors, by Application, Through 2026
Table 37 : Asia-Pacific Market for Kinase Inhibitors, by Country, Through 2026
Table 38 : ROW Market for Kinase Inhibitors, by Type, Through 2026
Table 39 : ROW Market for Tyrosine Kinase Inhibitor, by Type, Through 2026
Table 40 : ROW Market for Kinase Inhibitors, by Application, Through 2026
Table 41 : Revenue from Kinase Inhibitors, 2019-2020
Table 42 : Ongoing Clinical Trials of Various Kinase Inhibitors
Table 43 : Patents Filed for Kinase Inhibitors
Table 44 : AstraZeneca: Kinase Inhibitors Drugs Product Portfolio
Table 45 : Bayer AG: Kinase Inhibitors Drugs Product Portfolio
Table 46 : Boehringer Ingelheim: Kinase Inhibitors Drugs Product Portfolio
Table 47 : Bristol-Myers Squibb: Kinase Inhibitors Drugs Product Portfolio
Table 48 : Eisai Co.: Kinase Inhibitors Drugs Product Portfolio
Table 49 : F. Hoffmann-La Roche: Kinase Inhibitor Drugs Product Portfolio
Table 50 : Johnson & Johnson: Kinase Inhibitors Drugs Product Portfolio
Table 51 : Novartis AG: Kinase Inhibitor Drugs Product Portfolio
Table 52 : Pfizer: Kinase Inhibitor Drugs Product Portfolio
Table 53 : Abbreviations Used in This Report

List of Figures

Summary Figure A : Global Market Shares of Kinase Inhibitors, by Application, 2020
Summary Figure B : Global Market for Kinase Inhibitors, by Region, 2019-2026
Figure 1 : Estimated Numbers of New Cancer Cases in Women, 2020
Figure 2 : Estimated Numbers of New Cancer Cases in Men, 2020
Figure 3 : National Cancer Institute Research Funding, 2012-2019
Figure 4 : Impact of COVID-19 on Pharmaceutical Industry
Figure 5 : Global Market Shares of Kinase Inhibitors, by Type, 2020
Figure 6 : Global Market for Tyrosine Kinase Inhibitors, 2020-2026
Figure 7 : Global Market for Tyrosine Kinase Inhibitors, by Region, 2019-2026
Figure 8 : Global Market Shares of Tyrosine Kinase Inhibitors, by Type, 2020
Figure 9 : Global Market for Serine/Threonine Kinase Inhibitors, 2020-2026
Figure 10 : Global Market for Serine/Threonine Kinase Inhibitors, by Region, 2019-2026
Figure 11 : Global Market Shares of Kinase Inhibitors, by Application, 2020
Figure 12 : Global Market for Kinase Inhibitors Used as Antineoplastic Agents, 2020-2026
Figure 13 : Global Market for Kinase Inhibitors Used as Antineoplastic Agents, by Region, 2019-2026
Figure 14 : Global Market for Kinase Inhibitors Used in Age-related Macular Degeneration, 2020-2026
Figure 15 : Global Market for Kinase Inhibitors Used in Age-related Macular Degeneration, by Region, 2019-2026
Figure 16 : Global Market for Kinase Inhibitors Used as Immunosuppressants, 2020-2026
Figure 17 : Global Market for Kinase Inhibitors Used as Immunosuppressants, by Region, 2019-2026
Figure 18 : Global Market Shares of Kinase Inhibitors, by Region, 2020
Figure 19 : North American Market Shares of Kinase Inhibitors, by Type, 2020
Figure 20 : North American Market Shares of Kinase Inhibitors, by Application, 2020
Figure 21 : North American Market Shares of Kinase Inhibitors, by Country, 2020
Figure 22 : U.S. Market for Kinase Inhibitors, 2020-2026
Figure 23 : Canadian Market for Kinase Inhibitors, 2020-2026
Figure 24 : European Market Shares of Kinase Inhibitors, by Type, 2020
Figure 25 : European Market Shares of Kinase Inhibitors, by Application, 2020
Figure 26 : European Market Shares of Kinase Inhibitors, by Country, 2020
Figure 27 : German Market for Kinase Inhibitors, 2020-2026
Figure 28 : U.K. Market for Kinase Inhibitors, 2020-2026
Figure 29 : French Market for Kinase Inhibitors, 2020-2026
Figure 30 : Italian Market for Kinase Inhibitors, 2020-2026
Figure 31 : Spanish Market for Kinase Inhibitors, 2020-2026
Figure 32 : Rest of Europe Market for Kinase Inhibitors, 2020-2026
Figure 33 : Asia-Pacific Market Shares of Kinase Inhibitors, by Type, 2020
Figure 34 : Asia-Pacific Market Shares of Kinase Inhibitors, by Application, 2020
Figure 35 : Asia-Pacific Market Shares of Kinase Inhibitors, by Country, 2020
Figure 36 : Chinese Market for Kinase Inhibitors, 2020-2026
Figure 37 : Japanese Market for Kinase Inhibitors, 2020-2026
Figure 38 : Indian Market for Kinase Inhibitors, 2020-2026
Figure 39 : Rest of Asia-Pacific Market for Kinase Inhibitors, 2020-2026
Figure 40 : ROW Market Shares of Kinase Inhibitors, by Type, 2020
Figure 41 : ROW Market Shares of Kinase Inhibitors, by Application, 2020
Figure 42 : Global Market Share Analysis of Kinase Inhibitor, by Company, 2020
Figure 43 : Clinical Trial Phases of Various Kinase Inhibitors, 2020
Figure 44 : AstraZeneca: Annual Revenue, 2017-2020
Figure 45 : Bayer AG: Annual Revenue, 2017-2020
Figure 46 : Boehringer Ingelheim: Annual Revenue, 2017-2020
Figure 47 : Bristol-Myers Squibb: Annual Revenue, 2017-2020
Figure 48 : Eisai Co. Ltd.: Annual Revenue, 2017-2019
Figure 49 : F. Hoffmann-La Roche: Annual Revenue, 2017-2020
Figure 50 : Johnson & Johnson: Annual Revenue, 2017-2020
Figure 51 : Novartis AG: Financial Performance, 2017-2020
Figure 52 : Pfizer: Annual Revenue,2017-2020

当レポートのプレスリリースは発行されておりません。